Overview
WVE market data
Price History
WVE price chart · 1M
- O
- 5.24
- H
- 5.28
- L
- 5.04
- C
- 5.16
- Vol
- 214,212.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.24
- Previous Close
- $5.21
- Day High
- $5.28
- Day Low
- $5.04
- 52 Week High
- $7.61
- 52 Week Low
- $5.01
- 7 Day Return
- -1.81%
- 30 Day Return
- -12.39%
- 90 Day Return
- -21.52%
- 1 Year Return
- -26.81%
- Daily Notional Volume
- $1.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.50 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -309.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.01 – $21.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1B · P/B 5.91 · P/S 15.80.
Company News
8-K12B filing — Wave Life Sciences, Inc. (WVE)SEC EDGAR · Aug 7, 2026, 8:52 PM
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23Benzinga · Aug 4, 2026, 6:13 PM
Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $19Benzinga · Jul 31, 2026, 8:43 PM
B. Riley Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $22Benzinga · Jul 31, 2026, 3:42 PM
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12Benzinga · Jul 31, 2026, 1:02 PM
8-K filing — Wave Life Sciences Ltd. (WVE)SEC EDGAR · Jul 30, 2026, 11:38 AM
WAVE Life Sciences Q2 EPS $(0.34) Misses $(0.31) Estimate, Sales $2.272M Miss $7.050M EstimateBenzinga · Jul 30, 2026, 11:30 AM
Wave Life Sciences Initiates Phase 2a Multidose Portion Of INLIGHT Trial, Placebo-Controlled Study Evaluating WVE-007 As Monotherapy In Individuals Living With Obesity With High BMI And ComorbiditiesBenzinga · Jun 24, 2026, 12:40 PM